Yu D, Khan OF, Suvà ML, et al. Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression. Proc Natl Acad Sci U S A. 2017;114(30):E6147-E6156. doi:10.1073/pnas.1701911114
Gillette MA, Satpathy S, Cao S, et al. Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma. Cell. 2020;182(1):200-225.e35. doi:10.1016/j.cell.2020.06.013
Armenia J, Wankowicz SAM, Liu D, et al. The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2018;50(5):645-651. doi:10.1038/s41588-018-0078-z
Schaub FX, Dhankani V, Berger AC, et al. Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Cell Syst. 2018;6(3):282-300.e2. doi:10.1016/j.cels.2018.03.003
Porta-Pardo E, Kamburov A, Tamborero D, et al. Comparison of algorithms for the detection of cancer drivers at subgene resolution. Nat Methods. 2017;14(8):782-788. doi:10.1038/nmeth.4364
Xu H, Lee MS, Tsai PY, et al. Ablation of insulin receptor substrates 1 and 2 suppresses -driven lung tumorigenesis. Proc Natl Acad Sci U S A. 2018;115(16):4228-4233. doi:10.1073/pnas.1718414115
Filbin MG, Tirosh I, Hovestadt V, et al. Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science. 2018;360(6386):331-335. doi:10.1126/science.aao4750
Ding L, Bailey MH, Porta-Pardo E, et al. Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell. 2018;173(2):305-320.e10. doi:10.1016/j.cell.2018.03.033
Northcott PA, Buchhalter I, Morrissy S, et al. The whole-genome landscape of medulloblastoma subtypes. Nature. 2017;547(7663):311-317. doi:10.1038/nature22973
Cho SW, Xu J, Sun R, et al. Promoter of lncRNA Gene PVT1 Is a Tumor-Suppressor DNA Boundary Element. Cell. 2018;173(6):1398-1412.e22. doi:10.1016/j.cell.2018.03.068